“Global Respiratory Inhalers Market Set to Grow to $38bn by 2023” says new Visiongain report

09 April 2019
Pharma

Visiongain has launched a new pharma report Top 20 Global Respiratory Inhalers Manufacturers 2019: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Merck, Teva, Other Companies.

The global respiratory inhalers market is estimated to reach $38bn in 2023. In the respiratory Inhalers market the top three companies by revenue are GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, with 57.1% of the world market in 2018.

Inhalation therapy is the best option for lung diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). These local therapies allow the use of smaller doses and reduce systemic side effects. In the last two decades, a remarkable scientific interest in the technology for pulmonary delivery was spiked by the fact that the lungs can be used as a portal for systemic drug delivery.

The lead analyst of the report commented "Developments in treatment are expected to continue as new drugs and emerging technologies become more widely available. This may include personalised treatments for certain types of asthma not responding to the stepwise approach of the Global Initiative for Asthma (GINA) guidelines and treatments tailored to the specific composition of individual patient’s airway inflammation.

Inhaler technology will continue to innovate with ‘intelligent’ delivery systems allowing more precise targeting of specific areas of the lungs becoming more common. In addition, inhaler-based health monitoring devices providing feedback of inhaler use to patients and healthcare professionals offer the promise of improved treatment adherence and health outcomes."

Leading companies featured in the report include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Merck, Teva and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on + 44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever